XTL Biopharmaceuticals (NASDAQ: XTLB) Addresses Nasdaq Delisting Determination

February 27, 2026

Expert Analysis XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) has encountered a significant regulatory challenge following Nasdaq’s indication that the company may be classified as a “public shell,” a designation that threatens its continued listing. This development suggests that Nasdaq’s Listing Qualifications Department believes that XTL’s trading status no longer meets the requirements for an active and substantive listing. The classification as a shell entity often reflects limited operational activity or diminished…

Read More >>